?? CoLab #5 Waymo Than You Think: What the industry is talking about after J.P Morgan?
? Wow, what a start to 2025!
At #JPM25, AI took the stage, GLP-1s made headlines, and Waymo cars gave everyone a ride to the future.
With our own CEO Maya Zlatanova attending, we couldn’t resist making this a special edition of the CoLab newsletter.?
But this isn’t your typical executive summary. We’re pretty sure, you can Google the headlines about AI partnerships and blockbuster therapies. ;) Instead, we’re diving into the conversations that mattered and the key takeaways from industry leaders
Here are the community discussions worth joining:
1. Bill Hanlon , Head of RWD Product strategy at Labcorp
"The 2025 J.P. Morgan Healthcare Conference made one thing abundantly clear: the integration of real-world data (RWD) and lab test results is not just an asset in healthcare innovation—it’s the engine driving transformative change. In an era where precision medicine is the goal and speed is critical, the ability to combine lab results with other RWD sources is reshaping how therapies are discovered, developed, and deployed […] These examples are a testament to the growing realization across the industry: lab data isn’t just supplementary—it’s foundational. By integrating lab results with claims, EHRs, and patient-reported outcomes, we’re seeing companies uncover patterns that were invisible before."
2. Ross Muken , President of SOPHiA GENETICS
“Something felt very different this year at JPM (despite it still being THE GOAT). While I had my normal set of back to back meetings all week, attendance felt down noticeably. I know we are missing an entire sector of healthcare however, it still lacked the typical buzz of crowded hallways and impossible to navigate sidewalks. Many large companies clearly scaled back participants and the generalist investor felt totally absent (healthcare is not yet HOT again). I'm not sure if this is start of a trend or evidence of a sector still healing post several tough years. But it merits watching for 2026.
3. Stefano Bini , Academic Surgeon, Sensor/AI researcher and Advisor
“The lesson I (re) learned at #JPM2025 is to be curious. You simply never know where a random conversation will take you. JPM attracts a very specific person. It is not a sales event with vendors and their products. We have CES for that. JPM is about making deals and the people who attend are in leadership roles […] The real magic at JPM happens when curiosity breaks this cycle. These are the smartest people in the health sciences, surely there is something to learn? Asking “What’s your mission?” or “What are your goals?” can unlock fascinating stories, spark fresh ideas, and lead to unexpected partnerships. You may hear a concise “master class” from a world expert or see a connection that might not otherwise surface…”
领英推荐
4. Karen Knudsen MBA PhD , C-suite Healthcare Executive American Cancer Society
“spending today diving in more deeply into the new U.S. Department of Health and Human Services (HHS) AI Strategic Plan, and alignment with all the AI- centered discussions last week's J.P. Morgan Healthcare Conference. By my count, ~20% of presentations at JPM focused on AI innovations-- from clinical applications to operational efficiencies. This feels like a pivotal moment (or perhaps, a launching point?!) for AI in healthcare.”
?? Read Karen’s Post AI’s Pivotal Moment
?? What Everyone’s Talking About (In Between the Business Stuff)
Waymo’s Self-Driving Cars
The buzz around San Francisco’s streets highlighted parallels between AI in transport and healthcare innovation. These vehicles demonstrated how algorithms can now navigate the notoriously challenging roads of San Francisco! ??
How crazy is JPM25, you ask?
Nimi Vashi says "This is the line outside just one of many 9:00 PM meetups"
Let’s Bring Research Closer to Patients
1 个月It's indeed impressive to see these driverless cars around ?? But what was more impressive are all these innovative biotech companies all fighting diseases in such creative ways ??
Did we miss any buzzing conversations or standout insights from JPM25? Drop your favorite threads or takeaways here—we’d love to keep the discussion going and share even more perspectives!